P-2062. Hepatitis B Serostatus in the New York City Jail System, 2019–2023

Abstract Background Prevalence estimates of hepatitis B virus (HBV) infection, immunity, and vaccine eligibility in jails vary widely and are not well studied. Jails house individuals from marginalized communities who face high burdens of comorbid conditions, including substance use disorders, HIV, and hepatitis C (HCV), which all share risk factors for HBV. Assessing HBV serostatus in a large urban jail provides critical insights to effective screening and prevention initiatives. This study describes HBV serostatus among persons experiencing incarceration in the New York City (NYC) jail system. Methods This retrospective study includes all persons in the NYC jail system between October 2019 and December 2023 with HBV serologic testing in our system. Past HBV infection was defined as having HBV core (anti-HBc) antibody, and current HBV infection as surface antigen (HBsAg) positivity. HBV immunity was defined as having antibody to HBV surface antigen (anti-HBs), and HBV immunity by vaccination as having anti-HBs with no anti-HBc and no HBsAg. Select demographics and medical history were also examined and described. Results 2282 persons were included, 268 (11.7%) were women and 2014 (88.3%) were men. In all, 619 (27.1%) had serologic evidence of past HBV infection. 91 (4.0%) had evidence of current infection. 1310 (57.4%) were immune, of whom 1002 (76.5%) were immune by vaccination. 645 (28.3%) persons had no evidence of past or current HBV infection or immunity and were susceptible to HBV. Among those susceptible to HBV, 81 (12.6%) were women, 143 (22.2%) were living with HIV, 183 (28.4%) had laboratory evidence of HCV exposure, and 429 (66.5%) had a history of select substance use disorders. Conclusion The majority of individuals in our cohort were immune to HBV (57.4%), with nearly three-quarters of those immune by vaccination. 4% of the cohort had serological testing indicating current infection. However, a much larger proportion (28.3%) was susceptible to HBV and vaccine-eligible. We found that a substantial portion of individuals eligible for vaccination had medical conditions associated with HBV risk. These findings underscore the importance of ongoing prioritization of HBV screening and prevention protocols in jail settings. Disclosures All Authors: No reported disclosures

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.2226
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-2062. Hepatitis B Serostatus in the New York City Jail System, 2019–2023

Raphael Simonson, Chibuzo Enemchukwu, Natalia Varela, Malia Mackey et al.
Open Forum Infectious Diseases
Hepatitis B Virus Studies
article

P-2062. Hepatitis B Serostatus in the New York City Jail System, 2019–2023

Raphael Simonson, Chibuzo Enemchukwu, Natalia Varela, Malia Mackey, Batya Koenigsberg
article en

Abstract

Abstract Background Prevalence estimates of hepatitis B virus (HBV) infection, immunity, and vaccine eligibility in jails vary widely and are not well studied. Jails house individuals from marginalized communities who face high burdens of comorbid conditions, including substance use disorders, HIV, and hepatitis C (HCV), which all share risk factors for HBV. Assessing HBV serostatus in a large urban jail provides critical insights to effective screening and prevention initiatives. This study describes HBV serostatus among persons experiencing incarceration in the New York City (NYC) jail system. Methods This retrospective study includes all persons in the NYC jail system between October 2019 and December 2023 with HBV serologic testing in our system. Past HBV infection was defined as having HBV core (anti-HBc) antibody, and current HBV infection as surface antigen (HBsAg) positivity. HBV immunity was defined as having antibody to HBV surface antigen (anti-HBs), and HBV immunity by vaccination as having anti-HBs with no anti-HBc and no HBsAg. Select demographics and medical history were also examined and described. Results 2282 persons were included, 268 (11.7%) were women and 2014 (88.3%) were men. In all, 619 (27.1%) had serologic evidence of past HBV infection. 91 (4.0%) had evidence of current infection. 1310 (57.4%) were immune, of whom 1002 (76.5%) were immune by vaccination. 645 (28.3%) persons had no evidence of past or current HBV infection or immunity and were susceptible to HBV. Among those susceptible to HBV, 81 (12.6%) were women, 143 (22.2%) were living with HIV, 183 (28.4%) had laboratory evidence of HCV exposure, and 429 (66.5%) had a history of select substance use disorders. Conclusion The majority of individuals in our cohort were immune to HBV (57.4%), with nearly three-quarters of those immune by vaccination. 4% of the cohort had serological testing indicating current infection. However, a much larger proportion (28.3%) was susceptible to HBV and vaccine-eligible. We found that a substantial portion of individuals eligible for vaccination had medical conditions associated with HBV risk. These findings underscore the importance of ongoing prioritization of HBV screening and prevention protocols in jail settings. Disclosures All Authors: No reported disclosures

Open Forum Infectious DiseasesVol. 13(Supplement_1)
New York City Health and Hospitals Corporation (US)
Good health and well-being
Openalex Percentile: Top 91%
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.